Ingevity (NGVT) Aandelenoverzicht
Ingevity Corporation produceert en verkoopt actieve koolproducten, afgeleide speciale chemicaliën en polymeren in Noord-Amerika, Azië, Europa, het Midden-Oosten, Afrika en Zuid-Amerika. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 3/6 |
| Toekomstige groei | 3/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 3/6 |
| Dividenden | 0/6 |
NGVT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Ingevity Corporation Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$68.58 |
| 52 Week Hoogtepunt | US$79.29 |
| 52 Week Laag | US$39.74 |
| Bèta | 1.24 |
| 1 maand verandering | -8.24% |
| 3 maanden verandering | -4.79% |
| 1 Jaar Verandering | 60.20% |
| 3 jaar verandering | 44.53% |
| 5 jaar verandering | -18.86% |
| Verandering sinds IPO | 155.32% |
Recent nieuws en updates
Seeking Alpha • May 19
Ingevity - Shrinking To Grow
Summary Ingevity is pursuing a shrink-to-grow strategy, divesting non-core assets to boost focus and margins. Recent asset sales fetched modest prices, following significant impairment charges, but have not materially impacted earnings. Ingevity´s leverage is gradually declining, with 2026 guidance targeting $4.70–$5.20 EPS and $370–$395 million adjusted EBITDA. I remain cautiously optimistic, seeing potential for re-rating if further simplification or a performance materials spin-off occurs. Read the full article on Seeking Alpha
Narratiefupdate • May 14
NGVT: Future P/E Will Reward Margin Strength Despite Recent Impairment Charge
Analysts have raised Ingevity's price target from $80.50 to $85.50, citing updated assumptions for discount rates, revenue growth, profit margins, and future P/E that they believe more accurately reflect the stock's risk and earnings profile. What's in the News Ingevity reaffirmed earnings guidance for full year 2026, with expected net sales in a range of $1.05b to $1.15b (company guidance).Narratiefupdate • Apr 28
NGVT: Future P/E Will Reflect Margin Resilience And Impairment Charge Impact
Analysts have increased their price target for Ingevity to $80.50 from $79.25, citing updated assumptions on long term revenue growth, profit margin resilience, and future P/E levels reflected in recent research, including the Wells Fargo target increase. Analyst Commentary Recent research behind the new US$80.50 price target focuses on refreshed assumptions for long term revenue trends, margin resilience, and the P/E level that investors may be willing to ascribe to Ingevity over time.Narratiefupdate • Apr 11
NGVT: Future P/E Will Depend On Margin Execution And Impairment Fallout
Analysts have raised their price target on Ingevity by $5 to $79.25, citing updated assumptions regarding discount rates, long-term revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts raising the price target to $79.25 are updating their models to reflect changes in discount rates, long term revenue assumptions, profit margins, and future P/E expectations.Recent updates
Seeking Alpha • May 19
Ingevity - Shrinking To Grow
Summary Ingevity is pursuing a shrink-to-grow strategy, divesting non-core assets to boost focus and margins. Recent asset sales fetched modest prices, following significant impairment charges, but have not materially impacted earnings. Ingevity´s leverage is gradually declining, with 2026 guidance targeting $4.70–$5.20 EPS and $370–$395 million adjusted EBITDA. I remain cautiously optimistic, seeing potential for re-rating if further simplification or a performance materials spin-off occurs. Read the full article on Seeking AlphaNarratiefupdate • May 14
NGVT: Future P/E Will Reward Margin Strength Despite Recent Impairment Charge
Analysts have raised Ingevity's price target from $80.50 to $85.50, citing updated assumptions for discount rates, revenue growth, profit margins, and future P/E that they believe more accurately reflect the stock's risk and earnings profile. What's in the News Ingevity reaffirmed earnings guidance for full year 2026, with expected net sales in a range of $1.05b to $1.15b (company guidance).Narratiefupdate • Apr 28
NGVT: Future P/E Will Reflect Margin Resilience And Impairment Charge Impact
Analysts have increased their price target for Ingevity to $80.50 from $79.25, citing updated assumptions on long term revenue growth, profit margin resilience, and future P/E levels reflected in recent research, including the Wells Fargo target increase. Analyst Commentary Recent research behind the new US$80.50 price target focuses on refreshed assumptions for long term revenue trends, margin resilience, and the P/E level that investors may be willing to ascribe to Ingevity over time.Narratiefupdate • Apr 11
NGVT: Future P/E Will Depend On Margin Execution And Impairment Fallout
Analysts have raised their price target on Ingevity by $5 to $79.25, citing updated assumptions regarding discount rates, long-term revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts raising the price target to $79.25 are updating their models to reflect changes in discount rates, long term revenue assumptions, profit margins, and future P/E expectations.Narratiefupdate • Mar 28
NGVT: Higher P/E Will Rely On Future Margin Delivery
Analysts have lifted their price target on Ingevity by $5 to $79.25, citing updated assumptions on discount rates, long term revenue growth, profit margins, and future P/E, which support a slightly higher valuation outlook. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as consistent with updated assumptions on discount rates and long term revenue growth, which they believe better reflect the company’s current risk profile and earnings potential.Narratiefupdate • Mar 13
NGVT: Higher P/E Outlook Will Depend On Margin Execution
Analysts have raised their price target on Ingevity by $8.50 to $79.25, citing updated views on revenue growth, profit margins, and an expected higher future P/E multiple. Analyst Commentary Recent Street research has focused on how Ingevity might justify a higher valuation, with specific attention on revenue trends, profitability, and the potential for the shares to support a richer P/E multiple over time.Narratiefupdate • Feb 24
NGVT: Updated P/E Assumptions And Buybacks Will Shape Balanced Outlook
Analysts have raised their price target on Ingevity by $5 to $70.75, citing updated assumptions around discount rates and future P/E as the main factors behind this revised view. Analyst Commentary Analysts framing the new US$70.75 price target are focusing less on short term headlines and more on what updated discount rate and P/E assumptions imply for Ingevity's risk profile and execution needs.Narratiefupdate • Feb 09
NGVT: Share Repurchases And Battery Materials License Will Guide Balanced Outlook
Analysts have raised their price target on Ingevity from US$69.50 to US$70.75, citing updated assumptions around discount rates, revenue trends, profit margins and future P/E expectations. Analyst Commentary Analysts who support the higher price target describe it as a fine tuning of their models rather than a wholesale rethink.Narratiefupdate • Jan 26
NGVT: Buybacks And Battery Materials License Will Shape Balanced Outlook
Analysts have maintained their fair value estimate for Ingevity at US$69.50, with only minor adjustments to inputs such as the discount rate and long-term P/E assumptions. These changes reflect updated modeling rather than a change in conviction.Narratiefupdate • Jan 10
NGVT: Battery Additives And Buybacks Will Shape Balanced Long-Term Outlook
Analysts have adjusted their price target on Ingevity to US$69.50. This reflects updated views on the discount rate, revenue outlook, profit margins and future P/E assumptions.Narratiefupdate • Dec 25
NGVT: Future Battery Materials Role Will Drive Long-Term Upside Despite Margin Reset
Analysts have modestly raised their price target on Ingevity by about $1.25 to approximately $69.50. They cite a lower perceived discount rate and an improving revenue trajectory, which more than offset concerns about a structurally lower profit margin and a higher future valuation multiple.Narratiefupdate • Dec 10
NGVT: Future Battery Materials Role Will Drive Stronger Long Term Upside Potential
Analysts have nudged their price target on Ingevity higher from $65.25 to $68.25, citing a modestly richer future earnings multiple that more than offsets slightly softer revenue growth and margin assumptions. What's in the News Ingevity announced that Executive Vice President and Chief Financial Officer Mary Dean Hall will transition from her role effective May 1, 2026, and remain in an advisory capacity for one year, as part of a planned leadership change.Analyseartikel • Sep 30
Is There Now An Opportunity In Ingevity Corporation (NYSE:NGVT)?
While Ingevity Corporation ( NYSE:NGVT ) might not have the largest market cap around , it received a lot of attention...Analyseartikel • Sep 06
Does Ingevity (NYSE:NGVT) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Narratiefupdate • Sep 05
Portfolio Repositioning And Engineered Additives Will Create A Sustainable Future
Consensus analyst price targets for Ingevity have risen to $65.25, reflecting increased confidence in continued earnings and free cash flow growth following a strong Q2 beat and improved operational outlook. Analyst Commentary Q2 earnings beat, demonstrating stronger-than-expected financial performance.Narratiefupdate • Aug 06
Portfolio Repositioning And Engineered Additives Will Create A Sustainable Future
The upward revision in Ingevity's revenue growth forecasts from 2.6% to 3.7% per annum has outweighed the impact of a higher discount rate, resulting in an increased consensus analyst price target from $54.25 to $57.00. What's in the News Ingevity Corporation maintained its earnings guidance for 2025, expecting sales between $1.25 billion and $1.40 billion.Analyseartikel • Jun 27
Ingevity Corporation (NYSE:NGVT) Shares Could Be 39% Below Their Intrinsic Value Estimate
Key Insights The projected fair value for Ingevity is US$71.30 based on 2 Stage Free Cash Flow to Equity Ingevity's...Analyseartikel • May 28
Subdued Growth No Barrier To Ingevity Corporation (NYSE:NGVT) With Shares Advancing 33%
Those holding Ingevity Corporation ( NYSE:NGVT ) shares would be relieved that the share price has rebounded 33% in the...Nieuw narratief • May 27
Premium Markets Will Secure Long Term Value
Expansion into premium specialty chemicals and advanced materials is increasing margins and positioning for growth as sustainability trends and vehicle electrification accelerate.Analyseartikel • Apr 05
Why We're Not Concerned Yet About Ingevity Corporation's (NYSE:NGVT) 32% Share Price Plunge
Ingevity Corporation ( NYSE:NGVT ) shares have had a horrible month, losing 32% after a relatively good period...Analyseartikel • Feb 20
Ingevity (NYSE:NGVT) Has A Somewhat Strained Balance Sheet
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Analyseartikel • Jan 16
Ingevity Corporation (NYSE:NGVT) Shares Could Be 49% Below Their Intrinsic Value Estimate
Key Insights Ingevity's estimated fair value is US$82.84 based on 2 Stage Free Cash Flow to Equity Ingevity is...Analyseartikel • Nov 07
What Ingevity Corporation's (NYSE:NGVT) 32% Share Price Gain Is Not Telling You
Ingevity Corporation ( NYSE:NGVT ) shareholders have had their patience rewarded with a 32% share price jump in the...Analyseartikel • Oct 13
Is Ingevity (NYSE:NGVT) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analyseartikel • Sep 08
Ingevity Corporation's (NYSE:NGVT) Prospects Need A Boost To Lift Shares
When you see that almost half of the companies in the Chemicals industry in the United States have price-to-sales...Seeking Alpha • Aug 27
Ingevity: The Risk-Reward Ratio Is Still Unfavorable
Summary Ingevity, once considered a growth story, turned out to be a classic example of market cycles. While Road Technology and Performance Materials performed reasonably well in the first half of 2024, the Industrial Specialties segment dragged down revenue and net income. Given the company's significant debt burden, risk-averse investors should seek safer options within the chemical industry. Read the full article on Seeking AlphaAnalyseartikel • Aug 03
Ingevity Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
There's been a notable change in appetite for Ingevity Corporation ( NYSE:NGVT ) shares in the week since its quarterly...Analyseartikel • Jul 13
Ingevity (NYSE:NGVT) Use Of Debt Could Be Considered Risky
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyseartikel • Jun 14
Should You Investigate Ingevity Corporation (NYSE:NGVT) At US$45.90?
Ingevity Corporation ( NYSE:NGVT ), might not be a large cap stock, but it received a lot of attention from a...Analyseartikel • Apr 18
Are Investors Undervaluing Ingevity Corporation (NYSE:NGVT) By 44%?
Key Insights Ingevity's estimated fair value is US$78.59 based on 2 Stage Free Cash Flow to Equity Current share price...Analyseartikel • Mar 22
Is Ingevity (NYSE:NGVT) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analyseartikel • Jan 23
What Is Ingevity Corporation's (NYSE:NGVT) Share Price Doing?
Ingevity Corporation ( NYSE:NGVT ), might not be a large cap stock, but it saw a double-digit share price rise of over...Analyseartikel • Jan 04
Ingevity Corporation (NYSE:NGVT) Doing What It Can To Lift Shares
With a price-to-earnings (or "P/E") ratio of 12.6x Ingevity Corporation ( NYSE:NGVT ) may be sending bullish signals at...Analyseartikel • Nov 10
These Analysts Just Made An Incredible Downgrade To Their Ingevity Corporation (NYSE:NGVT) EPS Forecasts
The latest analyst coverage could presage a bad day for Ingevity Corporation ( NYSE:NGVT ), with the analysts making...Rendement voor aandeelhouders
| NGVT | US Chemicals | US Markt | |
|---|---|---|---|
| 7D | 5.2% | 1.4% | 1.3% |
| 1Y | 60.2% | 8.4% | 27.7% |
Rendement versus industrie: NGVT overtrof de US Chemicals industrie, die het afgelopen jaar een rendement 8.4 % opleverde.
Rendement versus markt: NGVT overtrof de US markt, die het afgelopen jaar een rendement opleverde van 27.7 %.
Prijsvolatiliteit
| NGVT volatility | |
|---|---|
| NGVT Average Weekly Movement | 5.3% |
| Chemicals Industry Average Movement | 7.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stabiele aandelenkoers: NGVT heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van NGVT is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1964 | 1,500 | Dave Li | www.ingevity.com |
Ingevity Corporation produceert en verkoopt actieve koolproducten, afgeleide speciale chemicaliën en polymeren in Noord-Amerika, Azië-Pacific, Europa, het Midden-Oosten, Afrika en Zuid-Amerika. Het bedrijf is actief in drie segmenten: Performance Materials, Performance Chemicals en Advanced Polymer Technologies. Het segment Performance Materials ontwerpt, produceert en verkoopt op hardhout gebaseerde en chemisch geactiveerde koolstofproducten voor gebruik in emissieregelsystemen voor benzinedampen in auto's, vrachtwagens, motorfietsen en boten.
Ingevity Corporation Samenvatting
| NGVT fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$2.40b |
| Inkomsten(TTM) | -US$156.00m |
| Inkomsten(TTM) | US$1.18b |
2.0x
P/S-verhouding-15.3x
Koers/WinstverhoudingIs NGVT overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| NGVT resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$1.18b |
| Kosten van inkomsten | US$711.70m |
| Brutowinst | US$466.00m |
| Overige uitgaven | US$622.00m |
| Inkomsten | -US$156.00m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -4.49 |
| Brutomarge | 39.57% |
| Nettowinstmarge | -13.25% |
| Schuld/Eigen Vermogen Verhouding | 2,842.9% |
Hoe presteerde NGVT op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/28 22:02 |
| Aandelenkoers aan het einde van de dag | 2026/05/28 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Ingevity Corporation wordt gevolgd door 8 analisten. 4 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Paretosh Misra | Berenberg |
| John McNulty | BMO Capital Markets Equity Research |
| Jonathan Tanwanteng | CJS Securities, Inc. |